Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1945 2
1947 1
1948 1
1949 2
1950 4
1951 9
1952 3
1953 3
1954 5
1955 2
1956 2
1957 2
1958 1
1960 1
1961 1
1963 3
1982 1
1985 3
1986 3
1987 3
1988 3
1989 6
1990 3
1991 12
1992 10
1993 6
1994 10
1995 9
1996 13
1997 10
1998 17
1999 16
2000 30
2001 23
2002 21
2003 23
2004 28
2005 26
2006 35
2007 55
2008 47
2009 60
2010 116
2011 181
2012 186
2013 200
2014 200
2015 225
2016 185
2017 204
2018 195
2019 194
2020 180
2021 133
2022 121
2023 103
2024 64

Text availability

Article attribute

Article type

Publication date

Search Results

2,594 results

Results by year

Filters applied: . Clear all
Page 1
Transdermal patches: Design and current approaches to painless drug delivery.
Al Hanbali OA, Khan HMS, Sarfraz M, Arafat M, Ijaz S, Hameed A. Al Hanbali OA, et al. Acta Pharm. 2019 Jun 1;69(2):197-215. doi: 10.2478/acph-2019-0016. Acta Pharm. 2019. PMID: 31259729 Free article. Review.
Therefore, a number of chemical approaches and physical techniques for transdermal patch development are under investigation....
Therefore, a number of chemical approaches and physical techniques for transdermal patch development are under investigation.. …
Efficacy of Diclofenac Transdermal Patch in Therapeutic Extractions: A Literature Review.
Awachat A, Shukla D, Bhola ND. Awachat A, et al. Cureus. 2022 Oct 18;14(10):e30411. doi: 10.7759/cureus.30411. eCollection 2022 Oct. Cureus. 2022. PMID: 36407136 Free PMC article. Review.
These include avoidance of first-pass metabolism, sustained and non-rapid absorption, steady plasma levels that remain for prolonged periods, lack of patient dependence on drugs, prevention of gastric distress, and flexibility of stopping delivery of medications by simply removin …
These include avoidance of first-pass metabolism, sustained and non-rapid absorption, steady plasma levels that remain for prolonged periods …
Rotigotine Transdermal Patch: A Review in Parkinson's Disease.
Frampton JE. Frampton JE. CNS Drugs. 2019 Jul;33(7):707-718. doi: 10.1007/s40263-019-00646-y. CNS Drugs. 2019. PMID: 31243728 Review.
Rotigotine (Neupro()), a non-ergolinic dopamine agonist (DA), is administered once daily via a transdermal patch (TP) that delivers the drug over a 24-h period. In the EU, the rotigotine TP is approved as monotherapy for the treatment of early Parkinson's disease (P …
Rotigotine (Neupro()), a non-ergolinic dopamine agonist (DA), is administered once daily via a transdermal patch (TP) that del …
Rotigotine Transdermal Patch: A Review in Restless Legs Syndrome.
Garnock-Jones KP. Garnock-Jones KP. Drugs. 2016 Jul;76(10):1031-40. doi: 10.1007/s40265-016-0601-4. Drugs. 2016. PMID: 27324269 Review.
Rotigotine transdermal patch (Leganto(), Neupro()) is indicated for the treatment of restless legs syndrome (RLS); this article reviews the pharmacological properties of rotigotine transdermal patch and its clinical efficacy and tolerability in patient …
Rotigotine transdermal patch (Leganto(), Neupro()) is indicated for the treatment of restless legs syndrome (RLS); this articl …
Asenapine Transdermal Patch for the Management of Schizophrenia.
Zhou M, Derakhshanian S, Rath A, Bertrand S, DeGraw C, Barlow R, Menard A, Kaye AM, Hasoon J, Cornett EM, Kaye AD, Viswanath O, Urits I. Zhou M, et al. Psychopharmacol Bull. 2020 Sep 14;50(4):60-82. Psychopharmacol Bull. 2020. PMID: 33012873 Free PMC article. Review.
Asenapine in its sublingual formulation was FDA approved for treatment of SZ and bipolar I disorder in adults in August of 2009 and has been proven to be both effective and safe. Transdermal patch of asenapine (Secuado) was FDA approved in October of 2019, the first …
Asenapine in its sublingual formulation was FDA approved for treatment of SZ and bipolar I disorder in adults in August of 2009 and has been …
Rotigotine transdermal patch and sleep in Parkinson's disease: where are we now?
Rosa-Grilo M, Qamar MA, Taddei RN, Pagonabarraga J, Kulisevsky J, Sauerbier A, Chaudhuri KR. Rosa-Grilo M, et al. NPJ Parkinsons Dis. 2017 Sep 5;3:28. doi: 10.1038/s41531-017-0030-4. eCollection 2017. NPJ Parkinsons Dis. 2017. PMID: 28890931 Free PMC article. Review.
This review provides an overview of several aspects of night-time sleep dysfunction in Parkinson's disease and describes all available published open-label and blinded studies that investigated the use of rotigotine transdermal patch targeting sleep. Blinded studies …
This review provides an overview of several aspects of night-time sleep dysfunction in Parkinson's disease and describes all available publi …
Rotigotine transdermal patch for the treatment of Parkinson's Disease.
Perez-Lloret S, Rey MV, Ratti PL, Rascol O. Perez-Lloret S, et al. Fundam Clin Pharmacol. 2013 Feb;27(1):81-95. doi: 10.1111/j.1472-8206.2012.01028.x. Epub 2012 Feb 9. Fundam Clin Pharmacol. 2013. PMID: 22320451 Review.
Application-site reactions were the most frequent adverse event, and they were considered mild to moderate in the majority of cases. The rotigotine transdermal patch offers a safe and efficacious alternative for the treatment of PD. Further studies should focus on t …
Application-site reactions were the most frequent adverse event, and they were considered mild to moderate in the majority of cases. The rot …
Rivastigmine transdermal patch 13.3 mg/24 h: a review of its use in the management of mild to moderate Alzheimer's dementia.
Frampton JE. Frampton JE. Drugs Aging. 2014 Aug;31(8):639-49. doi: 10.1007/s40266-014-0197-x. Drugs Aging. 2014. PMID: 24989628 Review.
Rivastigmine is unique among cholinesterase inhibitors commonly used in the treatment of mild to moderate Alzheimer's disease (AD) in that it is available as a transdermal patch formulation (Exelon() patch, Rivastach() patch, Prometax() patch). ...
Rivastigmine is unique among cholinesterase inhibitors commonly used in the treatment of mild to moderate Alzheimer's disease (AD) in that i …
Rivastigmine transdermal patch: a review of its use in the management of dementia of the Alzheimer's type.
Dhillon S. Dhillon S. Drugs. 2011 Jun 18;71(9):1209-31. doi: 10.2165/11206380-000000000-00000. Drugs. 2011. PMID: 21711064 Review.
Rivastigmine, a cholinesterase inhibitor, is available as a transdermal patch (Exelon() patch, Rivastach() patch, Prometax() patch) for the treatment of mild to moderate Alzheimer's disease. Rivastigmine transdermal patch was effective, in terms of imp …
Rivastigmine, a cholinesterase inhibitor, is available as a transdermal patch (Exelon() patch, Rivastach() patch, Prometax() p …
Rotigotine (Neupro) (Transdermal Patch).
[No authors listed] [No authors listed] Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2016 Nov. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2016 Nov. PMID: 28121102 Free Books & Documents. Review.
2,594 results